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Abstract
Background: We have empirically noted that many physi-
cians routinely request anti-phospholipid antibodies (aPL)
without a correct clinical indication. The aim of this study
was to evaluate retrospectively whether aPL testing at our
Thrombosis Centre was justified.
Methods: Medical records from 520 subjects for aPL screen-
ing tests for various clinical conditions were reviewed. The
aPL screening tests were: lupus anticoagulant (LA), anti-car-
diolipin antibodies (aCL) and anti-b2 glycoptotein I (ab2
GPI). Requests for aPL screening were divided into justified,
potentially justified or not adequately justified.
Results: aPL testing requests were considered justified in
358 (69%) patients, potentially justified in 66 (12.6%) and
not adequately justified in 96 (18.4%). LA was positive in
65 (18%) of justified requests and in only one (1%) of the
96 potentially justified requests. None of the 66 not ade-
quately justified for aPL testing was positive for LA. ab2
GPI was positive in 63 (17.6%) of the 358 justified, in four
(6%) of the 66 potentially justified and in five (5.2%) of the
96 not adequately justified requests; aCL IgG were positive
in 59 (16.4%) of the 358 justified and in five (7.5%) and six
(6.2%) of the potentially justified and not adequately justi-
fied requests, respectively. The presence of the triple aPL
positivity was found exclusively in the justified requests.
Conclusions: This study suggests that requests for aPL tests
should be addressed more adequately. This work could be an
example of how to focus attention on requests for laboratory
tests especially on the basis of valid clinical criteria before
the analyte is measured.
Keywords: anti-cardiolipin antibodies; anti-b2 glycoprotein
I antibodies; Dilute Russell’s viper venom time (dRVVT);
inadequate test request; silica clotting time (SCT).
*Corresponding author: Prof. Francesco Marongiu, Dipartimento
di Scienze Mediche Internistiche ‘‘M. Aresu’’, University of
Cagliari, SS 554, Monserrato 09042 (Cagliari), Italy
Phone: q39-706754188, Fax: q39-7051096201,
E-mail: marongiu@medicina.unica.it
Received July 1, 2010; accepted September 25, 2010;
previously published online February 9, 2011
Introduction
Laboratory investigation in the diagnosis of antiphospholipid
syndrome (APS) is based on the presence of lupus antico-
agulant (LA) in plasma and/or in combination with anti-car-
diolipin (aCL) and anti-b2 glycoprotein antibodies (ab2 GPI)
(1, 2). Taken together, they represent the laboratory pattern
of anti-phospholipid antibodies (aPL). Suggested indications
for aPL testing are: prolongation of activated partial throm-
boplastin time (APTT) mixing test with normal plasma,
venous or arterial thrombosis, especially if occurring before
the age of 50 years, thrombosis at unusual sites or associated
with autoimmune diseases, or complications of pregnancy
(2). However, a ‘‘grey zone’’ of potentially clinical utility
may exist in the case of autoimmune diseases. In particular,
there is good evidence that patients with systemic lupus ery-
thematosus (SLE) may acquire features of APS and vice-
versa (3). Requests for aPL testing in other conditions are,
in general, discouraged to avoid false-positive results (4–6).
The aims of this study were to evaluate retrospectively
whether aPL testing at our Thrombosis Centre (TC) between
July 2008 and August 2009 was justified and followed the
above criteria, and to analyse the physicians approach to aPL
testing which may be just one example of how laboratory
tests are excessively requested in daily clinical practise. In
general, the phenomenon of ordering superfluous tests is well
recognized, but it is difficult to contrast. Physicians often do
not know the meaning of the tests they order. This may be
the case with aPL (7).
Materials and methods
Patients
The records of 720 consecutive unselected subjects, referred to our
TC from July 2008 to August 2009 for aPL screening tests, were
considered. Two hundred records were excluded as the reasons for
the request were unknown. A total of 520 requests were considered.
The reasons for performing the tests were retrospectively identified
by consulting the medical records. Requests were divided into three
groups: justified (clinical evidence of thrombotic events and mis-
carriage), potentially justified (autoimmune disease without clinical
evidence of thrombotic events and miscarriage) or not adequately
justified (all other conditions).
Coagulation tests
Silica clotting time (SCT) The test consists of paired APTTs per-
formed on test plasmas with micronized silica (HaemosilTM Silica
Clotting Time, Instrumentation Laboratory, Milan, Italy) as activator
and two phospholipid concentrations (low SCT1 and high SCT2)
as platelet substitutes. The test was performed using an automated
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coagulometer (ACL Advance, International Laboratory, Milan, Ita-
ly) and is based on the ratio between the SCT screen and SCT
confirm. A SCT screen ratio was first calculated by dividing the
clotting time obtained in the patients using low SCT1 by the mean
clotting time obtained in a group of normal subjects. A SCT confirm
ratio was calculated by dividing the clotting time obtained in the
patients using high SCT2 by the mean clotting time obtained in a
group of normal subjects. A final ratio was obtained by dividing
the results of SCT screen by that of SCT confirm. If the cut-off
value of 1.21 was exceeded, the test was repeated after mixing 1:1
the plasma sample with normal plasma. It was considered positive
when a 1:1 mixture of test plasma and normal plasma yielded a
ratio more than 1.21. This cut-off value was calculated using the
99th percentile of coagulation times obtained in frozen plasma
samples from 50 healthy subjects.
Dilute Russell’s viper venom time (dRVVT) The test consists
of paired clotting times (HemosilTM dRVVT LAC screen and con-
firm, Instrumentation Laboratory, Milan, Italy) performed using an
automated coagulometer (ACL Advance, Instrumentation Labora-
tory, Milan, Italy). It is based on the ratio between the dRVVT
screen (low phospholipids concentration) and dRVVT confirm (high
phospholipids concentration). For the generation of the final ratio
we followed the same procedure described for SCT. It was consid-
ered positive when a 1:1 mixture of test plasma and normal plasma
yielded a ratio more than 1.34. This cut-off value was calculated
using the 99th percentile of coagulation times obtained in frozen
plasma samples from 50 healthy subjects.
ab2 GPI
IgG and IgM anti-b2 GPI antibodies were measured using ELISA
kits (EUROIMMUN Medizinische Labordiagnostika AG, Lu¨beck,
Germany). Concentrations of ab2 GPI antibodies were expressed in
units/mL and values of more than 8 and 12.5 were considered pos-
itive for IgM and IgG isotypes, respectively. The cut-off values have
been derived locally from 50 healthy subjects using the 99th
percentile.
aCL
The presence of IgG and IgM aCL were detected using quantitative
ELISA kits (Anticariolipine Bouty, Italy) according to the manufac-
turer’s instructions. Measured values of aCL were expressed in
units/mL, and values of more than 12 U/mL for either IgG or IgM
were considered positive. The cut-off values have been locally
derived from 95 healthy subjects using the 99th percentile.
Only abnormal tests (LA, aCL and ab2 GPI), confirmed after
3 months, were considered positive.
Statistical analysis
Statistical analysis was performed using MEDCALC software (ver-
sion 10.0.1.0). Data were expressed as median and range or
mean"SD where appropriate. Frequency data were compared using
Fisher’s exact test. p-Values -0.05 were considered statistically
significant.
Results
A total of 720 tests for an aPL screen performed in our TC
from July 2008 to August 2009 were examined. Requests for
520 of these requests were correctly detected by examining
the medical record. A total of 358 out of 520 requests for
aPL screening were considered as justified. Justified, poten-
tially justified and non-adequately justified requests are listed
in Table 1.
A total of 168 patients (32%) tested positive on two occa-
sions for at least one of the considered tests (dRVVT, SCT,
ab2 GPI, aCL). To determine whether the presence of aPL
was more prevalent in individuals with justified requests, the
distribution of test positivity in all groups (Table 2) was eval-
uated. Sixty-five (18%) of justified requests were positive
for SCT and/or dRVVT, only one (1%) of the 96 potentially
justified requests was positive for SCT, none of the 66 not
adequately justified were positive for SCT and/or dRVVT;
ab2 GPI was positive in 63 (17.6%) of the 358 justified, in
four (6%) of the 66 potentially justified and in five (5.2%)
of the 96 not adequately justified requests; aCL IgG was
positive in 59 (16.4%) of the 358 justified and in five (7.5%)
and six (6.2%) of the potentially justified and non-adequately
justified requests, respectively. When the combination of aPL
test was considered, the presence of triple aPL positivity, i.e.,
LA, aCL and a ab2 GPI was found exclusively in the ade-
quate request patients only. The other possible combinations
showed a higher frequency of aPL positivity in the group of
patients with an adequate request, but the differences were
not significant because the subgroups were too small.
Discussion
We have empirically noticed that many physicians routinely
request aPL screening for patients in whom these requests
do not seem to be adequate. We therefore questioned the
adequacy of aPL screening at our TC.
There are several reasons why physicians request aPL
screening for their patients in daily practice: the occurrence
(accidentally identified) of prolongation of the APTT without
known aetiology, to provide an explanation for arterial or
venous thrombosis, to assess the risk of miscarriage (preg-
nancy loss) recurrence, thrombosis in unusual sites or asso-
ciated with autoimmune diseases (2). These requests have
been classified in this study as justified. Even in autoimmune
diseases, requests for aPL may be ordered since a relation-
ship between some of these analytes and antiphospholipid
syndrome does exist (3). In this case, we classified the
requests as potentially justified.
Generalised searches on asymptomatic individuals other
than the above should be discouraged to avoid the risk of
false-positive results, of wasting time and resources, and of
obtaining a positive result which could be misleading in the
diagnosis and management of the single patient leading to
the use of inappropriate anti-thrombotic drugs. These
requests were classified as not justified.
Results of this retrospective study show that an important
percentage of potentially justified and not justified requests
were processed in our laboratory. In particular, only one
patient showed LA positivity in the group of patients with
potentially justified request, while none showed LA positi-
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Table 1 Justified, potentially justified and not adequately justified requests for aPL screening tests.
Diagnosis n %
Justified (ns358)
Deep venous thrombosis 98 18.9
Recurrent pregnancy losses 96 18.5
Antiphospholipid syndrome 47 9
Ischaemic stroke 33 6.3
Transient ischemic attack 31 5.9
Superficial venous thrombosis 16 3
Pulmonary embolism 16 3
Myocardial infarction 16 3
Avascular bone necrosis 3 0.5
Ischaemic neuritis 1 0.1
Prolonged APTT 1 0.1
Potentially justified (ns66)
Autoimmune diseasesa 66 12.6
Not adequately justified (ns96)
Artrhalgias or arthritis 27 5.1
Positivity for autoantibodies 13 2.5
Raynaud phenomenon 8 1.5
Familial history of thrombosis 7 1.3
Other conditionsb 18 3.4
aAutoimmune diseases: systemic lupus erythematosus (ns24, 36.3%), systemic sclerosis (ns27, 41%), rheumatoid arthritis (ns10, 15%),
Sjo¨gren’s syndrome (ns5, 7.5%), without clinical evidence of thrombotic events or pregnancy losses. bOther conditions: headache, infective
diseases, hepatitis, urticaria, venous insufficiency, dermatitis, ecchimosis, fever, neoplasm, erythema nodosum, pericarditis, aftosis.
Table 2 Distribution of aPL positivity in adequate and non-adequate requests.
Justified Potentially Not adequately
ns358 justified ns66 justified ns96
LA positivitya 65 (18.1%) 1 (1.5%) 0
LAqab2 GPIqaCL 46 0 0
LAqab2 GPI 3 0 1 (1%)
LAqaCL 3 0 0
ab2 GPI-IgGb 63 (17.6%) 4 (6%) 5 (5.2%)
ab2 GPI-IgM 59 (16.5%) 4 (6%) 7 (7.2%)
aCL IgG 59 (16.5%) 5 (7.5%) 6 (6.2%)
aCL IgM 47 (13.1%) 6 (9%) 10 (10.4%)
Values are given in numbers (percentage). LA, lupus anticoagulant; aCL, anticardiolipin antibody; ab2 GPI, anti-b2 glycoprotein antibody.
ap-0.0001 vs. potentially and not justified requests. bp-0.004 vs. potentially and not justified requests.
vity in the group of patients with unjustified requests. More-
over, it is worth noting that triple positivity (LA, aCL and
ab2 GPI) was absent in both the potentially justified and not
justified group, but present in the justified request group.
Ab2 GPI and aCL were present in the potentially justified
and not justified groups, but we observed that in different
combinations, LA was never present. Even though the group
of patients with a potentially justified request was small, our
results show that the percentage of positive aCL and ab2 GPI
tests was as low as that of the patients with unjustified
requests. It should be remembered that only LA was signif-
icantly associated with thromboembolism. Both aCL and ab2
GPI were found to not be so closely related with thrombo-
embolism (8, 9).
Requests for aCL and ab2 GPI appear less useful in the
management of the single patient without clinical and envi-
ronmental evidence of either a thrombotic event or foetal
loss. An educational program could be planned in order to
limit inappropriate aPL requests (10, 11). This approach has
been successfully adopted to improve, for instance, the
appropriateness of antiepileptic drug monitoring (12). A
computer-based intervention could be built, forcing physi-
cians to order aPL tests only if the clinical criteria of appro-
priateness are satisfied. A proposal for an algorithm is
presented in Figure 1. Requests for aPL testing should be
considered if there is clinical suspicion of APS. In particular,
LA testing should be the first test performed. If the request
is not justified, physicians should be discouraged from order-
ing aPL tests. In fact, asymptomatic cases meeting only the
laboratory criteria for APS are not to be treated with oral
anticoagulants. A particular condition may be that related to
patients with potentially justified requests, that is, those with
autoimmune disease. In these patients, ordering aPL testing
may be useful only if anti-thrombotic prophylaxis is required.
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Figure 1 Proposed algorithm for aPL screening.
This paper has some limitations. It is a retrospective study,
but we wanted to investigate the daily clinical and laboratory
practice of aPL testing at our TC with the aim of limiting
inappropriate requests in the future. We hope that this work
is an example of how to focus attention on the requests for
laboratory tests, especially on the basis of valid clinical cri-
teria to determine test appropriateness before it is measured.
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